2018 |
Ierardi et al. [43] |
8 |
Embolisation |
Onyx and coils in 3, NBCA and Onyx in 1, Onyx and coils in 1 |
100 (8/8) |
16.8 |
100 (8/8) |
2018 |
Stenson et al. [44] |
15 |
9 Embolisations 6 proximal extensions |
Onyx + coils |
100 9/9 |
36 |
– |
2017 |
van de Ham et al. [45] |
40 |
17 Embolisations 13 OC 10 Ch-EVAS |
Onyx ± coils |
96.5 (overall EL1 treatment) |
1–6 |
– |
2017 |
Marcelin et al. [23] |
9 |
Embolisation |
Onyx ± coils |
100 9/9 |
15.9 ± 11.36 |
89 8/9 |
2017 |
Ameli-Renani et al. [21] |
25 |
Embolisation |
Onyx ± coils |
100 (25/25) |
10 |
80–85 |
2017 |
Graif et al. [46] |
8 |
Embolisation 6 ELIa, 2 ELIb |
Onyx ± coils |
88 (7/8) |
6.9 |
71(5/7) |
2015 |
Gandini et al. [17] |
1 |
Transcaval Embolisation |
Cuff Zenith (Cook Medical, Bloomington, Ind) and thrombin and coils |
100 (1/1) |
12 |
100 (1/1) |
2014 |
Eberhardt et al. [47] |
8 |
Embolisation 6 ELIa, 1 ELIb, 1 ELIa & ELIb |
Onyx ± coils |
100 (8/8) |
13.2 (8–24) |
88 (7/8) |
2013 |
Katada et al. [48] |
1 |
Embolisation and cuff |
Coils NBCA-lipiodol embolisation was performed (B), then the Zenith TX2 extension cuff (Cook Medical, Bloomington, Ind) |
100 (1/1) |
6 |
100 (1/1) |
2011 |
Henrikson et al. [27] |
6 |
Embolisation 5 ELIa, 1 ELIb |
Onyx |
100% (6/6) |
3–18 |
100% (6/6) |
2011 |
Choi et al. [49] |
7 |
Embolisation and cuff |
N-BCA ± coils |
86% (6/7) |
18 (0–53 |
86% (6/7) |
2010 |
Lu et al. [50] |
42 |
Embolisation 5 ELIa, 1 ELIb, 1 EL1a & ELIb |
N-BCA or Onyx ± coils, fibrin glue injection |
98% (41/42) |
40 |
83% (35/42) |
2010 |
Grisafi et al. [51] |
1 |
Onyx |
Embolisation device, Onyx (Micro Therapeutics Inc, Irvine, Calif) |
100% (1/1) |
12 |
100% (1/1) |
2010 |
Loffroy et al. [52] |
1 |
Transarterial microcoil Embolisation |
Detachable microcoils into the nidus while an intra-aortic balloon catheter was inflated at the same time |
100% (1/1) |
6 |
100% (1/1) |
2005 |
Golzarian et al. [53] |
32 |
Embolisation 32 ELIa |
Coils with or without gelatin sponge or thrombin |
91% (29/32) |
38.6 |
91% (20/22) |
2003 |
Maldonandο et al. [54] |
17 |
Embolisation 13 ELIa, 4ELIb |
10 n-BCA, 3 coils, 4 cuff |
94% (16/17) |
6.9 (0–19) |
88% (15/17) |
1999 |
Amesur et al. [55] |
5 |
Embolisation 1 ELIa, 4 ELIb |
Coils |
100% (5/5) |
8 (3–17) |
100% (5/5) |